MX2016009613A - Seleccion de agentes moduladores del dolor gastrointestinal. - Google Patents

Seleccion de agentes moduladores del dolor gastrointestinal.

Info

Publication number
MX2016009613A
MX2016009613A MX2016009613A MX2016009613A MX2016009613A MX 2016009613 A MX2016009613 A MX 2016009613A MX 2016009613 A MX2016009613 A MX 2016009613A MX 2016009613 A MX2016009613 A MX 2016009613A MX 2016009613 A MX2016009613 A MX 2016009613A
Authority
MX
Mexico
Prior art keywords
selection
gastrointestinal pain
agents modulating
modulating gastrointestinal
reducing
Prior art date
Application number
MX2016009613A
Other languages
English (en)
Other versions
MX369105B (es
Inventor
Connolly Eamonn
Kunze Wolfgang
Bienenstock John
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of MX2016009613A publication Critical patent/MX2016009613A/es
Publication of MX369105B publication Critical patent/MX369105B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las presentes modalidades se refieren a la selección de agentes efectivos para reducir o prevenir el dolor gastrointestinal en un sujeto. Este agente se selecciona y se identifica si es capaz de reducir la activación espontánea y/o inducida del receptor de potencial transitorio vaniloide 1 (TRPV1).
MX2016009613A 2014-01-23 2015-01-23 Selección de agentes moduladores del dolor gastrointestinal. MX369105B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450065 2014-01-23
SE1450813 2014-07-01
PCT/SE2015/050064 WO2015112083A1 (en) 2014-01-23 2015-01-23 Selection of agents modulating gastrointestinal pain

Publications (2)

Publication Number Publication Date
MX2016009613A true MX2016009613A (es) 2016-11-08
MX369105B MX369105B (es) 2019-10-29

Family

ID=52465569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009613A MX369105B (es) 2014-01-23 2015-01-23 Selección de agentes moduladores del dolor gastrointestinal.

Country Status (19)

Country Link
US (3) US20160334391A1 (es)
EP (2) EP3629026B1 (es)
JP (1) JP6635925B2 (es)
KR (1) KR102154382B1 (es)
CN (1) CN106164674B (es)
AU (1) AU2015209763B2 (es)
BR (1) BR122023013786B1 (es)
CA (1) CA2936560C (es)
CL (1) CL2016001878A1 (es)
DK (1) DK3629026T3 (es)
ES (2) ES2767060T3 (es)
IL (1) IL246563B (es)
MX (1) MX369105B (es)
NZ (1) NZ721882A (es)
PL (1) PL3629026T3 (es)
RU (1) RU2692671C2 (es)
SG (1) SG11201605378TA (es)
UA (1) UA120846C2 (es)
WO (1) WO2015112083A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2018074514A1 (ja) * 2016-10-20 2018-04-26 ビオフェルミン製薬株式会社 腸管のイオン経細胞輸送体への作用剤、クロライドチャネル活性化剤、腎疾患の予防もしくは治療剤、又は排便促進剤
CN112739814B (zh) * 2018-07-24 2023-12-08 生命大地女神有限公司 使用能够增加腺苷水平的细菌菌株的治疗方法
CN117487686A (zh) * 2018-07-24 2024-02-02 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
CN111484982A (zh) * 2020-05-14 2020-08-04 西南民族大学 一种人结直肠腺癌细胞trpv1基因敲除细胞株及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289984B1 (it) 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
AU2006232931A1 (en) * 2005-04-01 2006-10-12 Board Of Trustees Of Southern Illinois University Intermetallic bonded diamond composite composition and methods of forming articles from same
US7344867B2 (en) 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
US20080051454A1 (en) 2006-04-21 2008-02-28 The Board Of Trustees Operating Michigan State University Compositions and methods for transient receptor potential vanilloid (TRPV) channel mediated treatments
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
WO2008090434A1 (en) 2007-01-25 2008-07-31 Pfizer Japan Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
EP2307042B1 (en) * 2008-06-25 2014-03-26 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
KR101091810B1 (ko) 2009-09-11 2011-12-12 고려대학교 산학협력단 신규 활성제를 이용한 ｔｒｐｖ1 활성화 방법
JP5681533B2 (ja) * 2011-03-14 2015-03-11 ビオフェルミン製薬株式会社 消化管痛の予防又は軽減剤
US8889659B2 (en) * 2011-09-09 2014-11-18 Api Genesis, Llc Pain relief compositions, manufacture and uses
JPWO2013141202A1 (ja) 2012-03-21 2015-08-03 独立行政法人国立精神・神経医療研究センター 筋増加剤、及び筋増加物質のスクリーニング方法

Also Published As

Publication number Publication date
AU2015209763B2 (en) 2020-12-24
EP3097423B1 (en) 2019-12-04
EP3097423A1 (en) 2016-11-30
EP3629026A1 (en) 2020-04-01
DK3629026T3 (da) 2021-05-17
AU2015209763A1 (en) 2016-07-21
UA120846C2 (uk) 2020-02-25
MX369105B (es) 2019-10-29
KR102154382B1 (ko) 2020-09-10
PL3629026T3 (pl) 2021-08-02
JP2017507651A (ja) 2017-03-23
US10656141B2 (en) 2020-05-19
BR112016016969A2 (pt) 2020-09-24
US11371985B2 (en) 2022-06-28
CA2936560A1 (en) 2015-07-30
SG11201605378TA (en) 2016-08-30
CA2936560C (en) 2021-06-01
US20160334391A1 (en) 2016-11-17
ES2767060T3 (es) 2020-06-16
JP6635925B2 (ja) 2020-01-29
IL246563A0 (en) 2016-08-31
WO2015112083A1 (en) 2015-07-30
RU2016134215A (ru) 2018-03-01
EP3629026B1 (en) 2021-02-24
NZ721882A (en) 2019-02-22
CN106164674B (zh) 2018-10-09
IL246563B (en) 2019-11-28
US20200225214A1 (en) 2020-07-16
ES2874479T3 (es) 2021-11-05
CN106164674A (zh) 2016-11-23
BR122023013786B1 (pt) 2023-12-12
RU2692671C2 (ru) 2019-06-26
KR20160111992A (ko) 2016-09-27
CL2016001878A1 (es) 2017-10-20
RU2016134215A3 (es) 2018-09-28
US20180259503A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
GB2546432A (en) Apertured fibrous structures and methods for making same
MX2020006115A (es) Inhibidores de la vía de respuesta al estrés integrada.
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
PH12016501578A1 (en) Pharmaceutical compounds
TW201614041A (en) Compositions for electronic devices
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX369105B (es) Selección de agentes moduladores del dolor gastrointestinal.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12019500376A1 (en) Acid-alpha glucosidase variants and uses thereof
PH12017500836A1 (en) Transdermal formulations
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
AU363883S (en) Tracking device
PH12020550081A1 (en) Transdermal formulations
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CO2019006113A2 (es) Pulverizador
MX2017000862A (es) Formulacion de factor viii.
UY36107A (es) Composición microencapsulada inhibidora de la nitrificación

Legal Events

Date Code Title Description
FG Grant or registration